| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Hemato-Oncology Unit and Laboratory of Pediatric Oncology, Hôpital Universitaire des Enfants, and
Laboratory of Hematology, Hôpital Brugman, Brussels, Belgium
Anti-inflammatory activities of pituitary adenylate cyclase-activating protein (PACAP) are mediated in part through specific effects on lymphocytes and macrophages. This study shows that in human polymorphonuclear neutrophils (PMNs), PACAP acts as a proinflammatory molecule. In PMNs, vaso-intestinal peptide/PACAP receptor 1 (VPAC-1) was the only receptor found to be expressed by RT-PCR. Using VPAC-1 Ab, we found that VPAC-1 mRNA was translated into proteins. In PMNs, PACAP increases cAMP, inositol triphosphate metabolites, and calcium. It activates two of the three members of the MAPK superfamily, the ERK and the stress-activated MAPK p38. U73122, an inhibitor of phospholipase C (PLC), inhibits PACAP-induced ERK activation, whereas p38 MAPK phosphorylation was unaffected. Using specific pharmalogical inhibitors of ERK (PD098059) and p38 MAPK (SB203580), we found that PACAP-mediated calcium increase was ERK and PLC dependent and p38 independent. PACAP primes fMLP-associated calcium increase; it also primes fMLP activation of the respiratory burst as well as elastase release, these last two processes being ERK and PLC dependent and p38 MAPK independent. PACAP also increases membrane expression of CD11b and release of lactoferrin and metallo proteinase-9 (MMP-9). These effects were PLC dependent (CD 11b, lactoferrin, MMP-9), ERK dependent (CD 11b, lactoferrin, MMP-9), and p38 dependent (CD11b, lactoferrin). We conclude that PACAP is a direct PMN activator as well as an effective PMN priming agent that requires PLC, ERK, and p38 MAPK activities.
This article has been cited by other articles:
|
|
 |
|
  K. Chakraborty, P. C. Maity, A. K. Sil, Y. Takeda, and S. Das cAMP Stringently Regulates Human Cathelicidin Antimicrobial Peptide Expression in the Mucosal Epithelial Cells by Activating cAMP-response Element-binding Protein, AP-1, and Inducible cAMP Early Repressor J. Biol. Chem., August 14, 2009; 284(33): 21810 - 21827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. El Zein, B. Badran, and E. Sariban VIP differentially activates {beta}2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1 J. Leukoc. Biol., April 1, 2008; 83(4): 972 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Michalski, F. Selvaggi, M. Bartel, T. Mitkus, A. Gorbachevski, T. Giese, P. D. Sebastiano, N. A. Giese, and H. Friess Altered anti-inflammatory response of mononuclear cells to neuropeptide PACAP is associated with deregulation of NF-{kappa}B in chronic pancreatitis Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G50 - G57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kim, B. D. Lee, O. Kim, Y.-S. Bae, T. Lee, P.-G. Suh, and S. H. Ryu Pituitary adenylate cyclase-activating polypeptide 27 is a functional ligand for formyl Peptide receptor-like 1. J. Immunol., March 1, 2006; 176(5): 2969 - 2975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Harfi, F. Corazza, S. D'Hondt, and E. Sariban Differential Calcium Regulation of Proinflammatory Activities in Human Neutrophils Exposed to the Neuropeptide Pituitary Adenylate Cyclase-Activating Protein J. Immunol., September 15, 2005; 175(6): 4091 - 4102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ueno, K. Fukatsu, Y. Maeshima, T. Moriya, E. Shinto, E. Hara, H. Nagayoshi, H. Hiraide, and H. Mochizuki Dietary Restriction Compromises Resistance to Gut Ischemia-Reperfusion, Despite Reduction in Circulating Leukocyte Activation JPEN J Parenter Enteral Nutr, September 1, 2005; 29(5): 345 - 352. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
